Stocks
Fate Therapeutics (FATE) EV/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -11.8 | -56.5 | -23.4 | -2.11 | -0.98 | -0.30 | ||
| Changes by years, y/y, % | +43% | +378% | -59% | -91% | -53% | -34.7% | |||
Fate Therapeutics. EV/EBITDA
Fate Therapeutics. EV/EBITDA, changes, %
Fate Therapeutics (FATE) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | LTM ? | |||
| EV/EBITDA | ? | -0.86 | 0.18 | -0.89 | -2.32 | -1.00 | -0.30 | |
| Changes by years, y/y, % | -89% | -103% | -59% | +127% | +17% | |||
| Changes by quarters, q/q, % | -16% | -121% | -591% | +161% | -57% | |||
